The third quarter performance forecast of medical device listed companies has been disclosed one after another, and the overall growth has been maintained

【Pharmaceutical Network Industry News】On November 11, Mindray, a leading medical device company, disclosed its performance forecast for the third quarter of this year, saying that the company is expected to achieve revenue of about 7.
9 billion yuan in the first half of the year, a year-on-year increase of about 20%; The net profit attributable to shareholders of listed companies is expected to be about 2.
8 billion yuan, a year-on-year increase of about 20%.

As for the reasons for the growth of performance, the company said that it mainly benefited from the vigorous development of domestic medical infrastructure and the continuous recovery of global routine business, while the company continued to strengthen internal management, continued to improve operating efficiency, and achieved stable and healthy growth
in the company's operating income and net profit.
Recently, listed companies have successively disclosed the third quarter performance forecast and performance express period, up to now, a number of medical device listed companies have disclosed relevant data, overall, the medical device industry in the first three quarters of the overall performance maintained growth
。 In addition to Mindray, for example, according to the prospectus of MyHome Medical listed on the Growth Enterprise Market on October 12, 2022, the company expects its operating income in the first three quarters of this year to be 970 million yuan to 1.
11 billion yuan, a year-on-year increase of 17.
68% to 34.
66%.
The net profit attributable to the parent is expected to be 270 million yuan to 310 million yuan, a year-on-year increase of 14.
53% to 31.
49%; Non-net profit was 266 million yuan to 303 million yuan, a year-on-year increase of 15.
42% to 31.
47%.

As for the reasons for the increase in performance, the company said that the main reason is that the company's downstream customers have sufficient orders, and the company's production capacity has increased after the Huizhou base is put into operation, which has led to an increase
in revenue.
On the evening of September 18, CapBio disclosed its performance forecast for the first three quarters, and it is expected that the net profit attributable to shareholders of listed companies in the first three quarters will be 1.
35 billion yuan to 1.
45 billion yuan, a year-on-year increase of 108.
68%-124.
14%; The net profit attributable to shareholders of listed companies before non-recurring profits and losses reached 1.
337 billion yuan to 1.
437 billion yuan, a year-on-year increase of 112.
37% to 128.
25%.

The rapid growth of performance is mainly due to the increase in demand for nucleic acid testing, which has driven sales of sampling consumables and nucleic acid extraction reagents
.
In addition, BGI, which was previously happy, predicts that in the first three quarters of this year, the company is expected to achieve a net profit of 1.
89-2.
02 billion yuan, a year-on-year increase of 311.
8%-340.
1%.

While the performance of listed companies is expected to be happy, since September, affected by the introduction of the "subsidized loan" policy, the medical device industry has once again been pushed to the forefront
.
At present, the investment value of the medical device sector has been recognized by the market, with an increase of nearly 10%
in the week before the holiday.
Mindray said in an intensive survey by institutions recently that up to now, more than 200 billion yuan of medical equipment loan demand has been reported nationwide, and it is expected that the loan demand related to the company's products will exceed 20 billion yuan
.
It is expected that the domestic demand for medical equipment procurement is expected to be released rapidly in the next 1-2 years, or drive the performance of related targets to achieve accelerated growth
.
Institutions are also optimistic about the opportunities
brought by policies to the medical device industry.
Founder Securities believes that the financial subsidized loan is expected to release the procurement demand of medical institutions in a phased manner, and promote the peak period of medical equipment procurement in the fourth quarter of
this year and next year.
Caixin Securities also said that new medical infrastructure is a major trend in the construction of the national medical system, and the prosperity spreads from the front-end civil construction to the back, and related enterprises such as medical special projects, medical equipment, and medical informatization will also benefit one after another; At the same time, in the post-epidemic era, the world has strengthened public health construction, adapted to the wave of new medical infrastructure, and also provided development opportunities for domestic medical device products to go overseas, and the internationalization process of the medical device industry has continued to accelerate
.
Data show that in recent years, the scale of China's medical device industry has shown a rapid growth trend, from 370 billion yuan in 2016 to 850 billion yuan in 2020, with an average annual compound growth rate of about 23.
11%, and is expected to reach 1,294.
5 billion yuan
by 2025.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.